Roadshow
FB825
FB825 is a first-in-class antibody targeting IgE B cells for the treatment of allergic diseases. It specifically binds to the CεmX domain on the membrane-bound IgE B cells and induces the apoptosis and ADCC of the targeted cells.
Join us at BIO 2024, June 3-6 in San Diego, where Oneness Biotech Co., Ltd. will be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 1917. See you there! #BIO2024#TAIWAN PAVILION
FB825
Indications: IgE-related allergic diseases such as atopic dermatitis, allergic asthma, hyper-IgE syndrome, and food allergies
Mechanism of Action: Treats and prevents allergic diseases by inhibiting the B lymphocytes, which express mIgE
Current Status:
- Completed a phase I clinical trial in the US
- Completed a phase II a clinical trial of atopic dermatitis in the US
- A phase II a clinical trial in allergic asthma in Taiwan is ongoing
- A phase II clinical trial of the subcutaneous injection formulation for moderate to severe atopic dermatitis in Taiwan and the United States is ongoing
Product Advantages:
- Uniqueness: Has a novel drug target and mechanism by inhibiting the source of IgE, i.e., the mIgE B cells.
- Safety: Has a specific pharmacological mechanism and limited side effects.
- Extensive use: Has a wide range of indications and applies to more allergy and asthma patients than its existing counterparts.
- Economy: FB825 has excellent pharmacokinetic properties and a long half-life. It is anticipated to be administered once every 2-3 months. The long-acting advantage provides great convenience to patients and helps reduce medical costs.
Market Potentials:
According to analysis reports by Allied Market Research and Coherent Market Insights, the global market size of atopic dermatitis/asthma treatment will reach USD 38 billion in 2027.
R & D Progress:
- #Atopic Dermatitis
- #Allergic Asthma
- #Dermatology
- #Hyper IgE
- Established 2008
- Company Oneness Biotech Co., Ltd.
- Telephone +886-2-2703-1098
- Email zoe.chen@onenessbio.com.tw
- Address 35F., No. 66, Sec. 1, Zhongxiao W. Rd., Zhongzheng Dist., Taipei City 100507, Taiwan
About Oneness
Founded in 2008, Oneness Biotech is a leading biotech in Taipei, Taiwan developing game-changing therapeutics in chronic dermatological and immunological disorders. It went IPO since 2011, becoming a commercial stage biotech company with its lead product being commercialized globally in 2024.
- Innovative pipelines to provide game-changing solutions:
♦ON101 : First-in-class macrophage-regulator for millions of chronic wounds - ongoing global market expansion via partnership
♦FB825 : First-in-class anti-IgE B cell mAb out-licensed to LEO Pharma for US$530 M deal since 2020
♦FB704A : anti-IL6 mAb and SNS812, siRNA targeting coronaviruses in phase 2 stage validating in-house R&D capability bringing assets from pre-clinical to clinical
- Integrated platform with full-human antibody library, pre-clinical proof-of-concept capability and PIC/s GMP certified manufacturing facilities with production capacity of 25 million tubes of ON101 for global market
- Experienced leadership team in strategy, R&D and market access.
We strengthen our collaboration with global pharma companies based on our breakthrough innovation and science. Based in Taiwan, we hope to connect the world with our game-changing solutions and make contribution to human health.
